<DOC>
	<DOC>NCT02736162</DOC>
	<brief_summary>The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.</brief_summary>
	<brief_title>Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy</brief_title>
	<detailed_description>This study is a retrospective study of participants who received perampanel as primary or secondary monotherapy at approximately 40 centers in Europe, Asia, and Australia. Primary monotherapy is defined as the administration of perampanel in the absence of any concomitant antiepileptic drugs (AEDs). Secondary (conversion) monotherapy is defined as the conversion of perampanel from adjunctive therapy to monotherapy by withdrawing concomitant AEDs.</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Diagnosis of epilepsy Received perampanel as primary or secondary monotherapy at any time between 1 Jan 2013 and 15 Oct 2015 Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records per local requirements</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Perampanel</keyword>
	<keyword>E2007</keyword>
	<keyword>Phase 4</keyword>
	<keyword>Fycompa</keyword>
</DOC>